Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: NT-proBNP screening.
- Who it may be relevant to
- Registry conditions: Heart Failure, Diuretics. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Jersey
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey (FIND-HF LOOP)
Overview
The goal of this clinical trial is to learn whether a simple blood test screening pathway can help diagnose heart failure earlier in adults in primary care who take loop diuretic medicines (such as furosemide or bumetanide) but do not have a recorded diagnosis of heart failure. The main questions it aims to answer are: 1. Does offering a NT-proBNP blood test to eligible patients increase the number of new heart failure diagnoses within 12 months compared with usual care? 2. Does this screening pathway also uncover other important heart problems, such as irregular heart rhythms (arrhythmias) or valve disease? This is a cluster randomised controlled trial, which means that whole GP practices, rather than individual patients, are randomly assigned to one of two approaches: 1. NT-proBNP screening pathway, in which eligible patients are invited for a NT-proBNP blood test 2. Usual care, in which patients continue to be managed as they normally would without proactive screening Participants will: Be identified from GP records if they are prescribed loop diuretics and have no prior diagnosis of heart failure In screening practices, be invited to attend for a free finger-prick NT-proBNP blood test and brief questionnaire Be referred to the heart failure team and invited for an echocardiogram (a heart ultrasound scan) and further assessment if their NT-proBNP level is higher than 125 pg/mL Researchers will compare outcomes between screening and usual-care practices after 12 months, focusing on new diagnoses of heart failure. They will also look at other important cardiovascular findings, such as new arrhythmias, valve disease, and heart failure hospitalisation rates.
Interventions
- Diagnostic test NT-proBNP screening
Patients in the intervention arm will be invited for a free point of care NT-proBNP blood test
Primary outcome measures
- New Heart Failure diagnosis at 12 months [Time frame: 12 months from practice enrollment]
Secondary outcome measures (3)
- New clinically relevant cardiovascular disease [Time frame: 12 months]
- Heart Failure Hospitalisations [Time frame: 12 months]
- All cause mortality [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Receiving a loop diuretic (furosemide, bumetanide or torsemide)
- No coded diagnosis of heart failure in GP records
- Never had a natriuretic peptide test
- Willing to have a blood test for NT-proBNP
Exclusion criteria
- Clinical Frailty Score 7 or above on Rockwood frailty scale
- Prior diagnosis of heart failure
- Prior natriuretic peptide testing
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Jersey · 1 center
- Jersey General Hospital — Saint Helier
Identifiers
NCT: NCT07320677 · 2025HCJREC03